Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)

NCT02882984 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

325

Enrollment

OTHER

Sponsor class

Conditions

Stage IV EGFR Mutated NSCL With Brain Metastases

Interventions

DRUG: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
RADIATION: WBRT
RADIATION: HFSRS

Sponsor

Sichuan Provincial People's Hospital